**Supplementary Table S1.** Treatment-related adverse events (TRAEs)

|  |  |  |
| --- | --- | --- |
| *Systemic TRAEs* | Any Grade  n, (%) | Grade 3 or 4  n, (%) |
| Lymphopenia | 6 (24%) | 0 (0.0%) |
| Proteinuria | 4 (16%) | 0 (0.0%) |
| Hematuria | 3 (12%) | 0 (0.0%) |
| Hyperkalemia | 2 (8.0%) | 0 (0.0%) |
| Malaise / Fatigue | 1 (4.0%) | 0 (0.0%) |
| Headache | 1 (4.0%) | 0 (0.0%) |
| Hypokalemia | 1 (4.0%) | 0 (0.0%) |
| AST increased | 1 (4.0%) | 0 (0.0%) |
| ALT increased | 1 (4.0%) | 0 (0.0%) |
| ALP increased | 1 (4.0%) | 0 (0.0%) |
| Hypoalbuminemia | 1 (4.0%) | 0 (0.0%) |
| Note: Adverse events were graded according to the National Cancer Institute Common Toxicity Criteria for Adverse Events (CTCAE version 3.0). Abbreviations: AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase. | | |